The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma
Open accessAbstract
Background & Aims Well established risk factors for intrahepatic cholangiocarcinoma such as biliary tract inflammation and liver flukes are not present in most patients in Western countries. Although cirrhosis and other causes of chronic liver disease have been implicated, their contribution as risk factors for cholangiocarcinoma is unclear and our aims were to analyze these emerging potential risk factors by systematic examination of case-control series from geographically diverse regions. Methods We performed a literature review and meta-analysis of case-control studies on intrahepatic cholangiocarcinoma and cirrhosis and related risk factors. Tests of heterogeneity, publication bias and sensitivity analyses were performed and an overall odds ratio and 95% confidence intervals calculated. Results Eleven studies from both high and low prevalence regions were identified. All studies except for those evaluating cirrhosis, diabetes, and obesity exhibited significant heterogeneity. Cirrhosis was associated with a combined OR of 22.92 (95% CI = 18.24 – 28.79). Meta-analysis estimated the overall odds ratio (with 95% confidence intervals) for defined risk factors such as hepatitis B: 5.10 (2.91–8.95), hepatitis C: 4.84 (2.41–9.71), obesity: 1.56 (1.26–1.94), diabetes mellitus type II: 1.89 (1.74–2.07), smoking: 1.31 (0.95–1.82), and alcohol use: 2.81 (1.52–5.21). Sensitivity analysis did not alter the odds ratio for any risk factors except smoking and there was no evidence of publication bias. Conclusions Cirrhosis, chronic hepatitis B and C, alcohol use, diabetes, and obesity are major risk factors for intrahepatic cholangiocarcinoma. These data suggest a common pathogenesis of primary intrahepatic epithelial cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Self-citationRisk factors for cholangiocarcinoma
Tyson, G. L., & El-Serag, H. B. (2011) · Hepatology · doi:10.1002/hep.24351 · Cited by 956
The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update
El-Serag, H. B., Davila, J. A., Petersen, N. J., & McGlynn, K. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00009 · Cited by 943
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?
Shaib, Y. H., Davila, J. A., McGlynn, K., & El-Serag, H. B. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2003.11.030 · Cited by 683
Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study
Shaib, Y. H., El-Serag, H. B., Davila, J. A., Morgan, R., & McGlynn, K. A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.048 · Cited by 546
Welzel, T. M., Graubard, B. I., Zeuzem, S., El-Serag, H. B., Davila, J. A., & McGlynn, K. A. (2011) · Hepatology · doi:10.1002/hep.24397 · Cited by 543
Welzel, T. M., Graubard, B. I., El–Serag, H. B., Shaib, Y. H., Hsing, A. W., Davila, J. A., & McGlynn, K. A. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.020 · Cited by 514
Worldwide trends in mortality from biliary tract malignancies
Patel, T. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-10 · Cited by 491
Self-citationPrimary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential
Broomé, U., Löfberg, R., Veress, B., & Eriksson, L. S. (1995) · Hepatology · doi:10.1002/hep.1840220511 · Cited by 481
Cited by
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J.-W., Patel, T., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,511
Self-citationBanales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,307
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,153
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Saha, S. K., Zhu, A. X., Fuchs, C. S., & Brooks, G. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0446 · Cited by 786
Cholangiocarcinoma: Epidemiology and risk factors
Khan, S. A., Tavolari, S., & Brandi, G. (2019) · Liver International · doi:10.1111/liv.14095 · Cited by 783
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Bridgewater, J., Edeline, J., Kelley, R. K., Klümpen, H. J., Malka, D., Primrose, J. N., Rimassa, L., Stenzinger, A., Valle, J. W., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.506 · Cited by 718
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw324 · Cited by 675
Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Massarweh, N. N., & El-Serag, H. B. (2017) · Cancer Control · doi:10.1177/1073274817729245 · Cited by 634
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M.-C., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 610
Self-citationClements, O., Eliahoo, J., Kim, J. U., Taylor-Robinson, S. D., & Khan, S. A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.007 · Cited by 550
Choi, J.-Y., Lee, J.-M., & Sirlin, C. B. (2014) · Radiology · doi:10.1148/radiol.14132361 · Cited by 513
Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research
Chen, X., & Calvisi, D. F. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.002 · Cited by 434
Epidemiology of cholangiocarcinoma
Bergquist, A., & von Seth, E. (2015) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2015.02.003 · Cited by 400
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
Wardell, C. P., Fujita, M., Yamada, T., Simbolo, M., Fassan, M., Karlic, R., Polak, P., Kim, J., Hatanaka, Y., Maejima, K., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.009 · Cited by 373
Sapisochin, G., Facciuto, M., Rubbia‐Brandt, L., Marti, J., Mehta, N., Yao, F. Y., Vibert, E., Cherqui, D., Grant, D. R., Hernandez‐Alejandro, R., et al. (2016) · Hepatology · doi:10.1002/hep.28744 · Cited by 370
Liver resection and transplantation for intrahepatic cholangiocarcinoma
Mazzaferro, V., Gorgen, A., Roayaie, S., Droz dit Busset, M., & Sapisochin, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.020 · Cited by 355
Molecular Pathogenesis of Cholangiocarcinoma
Labib, P. L., Goodchild, G., & Pereira, S. P. (2019) · BMC Cancer · doi:10.1186/s12885-019-5391-0 · Cited by 310
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.147 · Cited by 306
Cancer and liver cirrhosis: implications on prognosis and management
Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000042 · Cited by 295
Liver cancer: Approaching a personalized care
Bruix, J., Han, K.-H., Gores, G., Llovet, J. M., & Mazzaferro, V. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.007 · Cited by 284
Petrick, J. L., Campbell, P. T., Koshiol, J., Thistle, J. E., Andreotti, G., Beane-Freeman, L. E., Buring, J. E., Chan, A. T., Chong, D. Q., Doody, M. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0007-z · Cited by 257
Petrick, J. L., Yang, B., Altekruse, S. F., Van Dyke, A. L., Koshiol, J., Graubard, B. I., & McGlynn, K. A. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186643 · Cited by 210
Proteome Landscapes of Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Yi, X., Zhu, J., Liu, W., Peng, L., Lu, C., Sun, P., Huang, L., Nie, X., Huang, S., Guo, T., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100604 · Cited by 25
Metadata
- Authors
- Palmer, W. C., & Patel, T.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 57
- Issue
- 1
- Pages
- 69-76
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1975960651
- Cited by
- 517
- References
- 33
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.